PJ Hampel, SA Parikh - Blood cancer journal, 2022 - nature.com
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton …
B Eichhorst, CU Niemann, AP Kater… - … England Journal of …, 2023 - Mass Medical Soc
Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …
T Munir, DA Cairns, A Bloor, D Allsup… - … England Journal of …, 2024 - Mass Medical Soc
Background The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …
O Al-Sawaf, S Robrecht, C Zhang, S Olivieri… - Blood …, 2024 - ashpublications.org
Venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients with previously untreated chronic lymphocytic leukemia (CLL). In the CLL14 study, patients with previously …
CU Niemann, T Munir, C Moreno, C Owen… - The Lancet …, 2023 - thelancet.com
Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously …
T Munir, C Moreno, C Owen, G Follows… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In GLOW, fixed-duration ibrutinib+ venetoclax showed superior progression-free survival (PFS) versus chlorambucil+ obinutuzumab in older/comorbid patients with …
M Fürstenau, YJ Thus, S Robrecht, CHM Mellink… - Blood, 2023 - ashpublications.org
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in …
H Huber, E Tausch, C Schneider, S Edenhofer… - Blood, 2023 - ashpublications.org
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …
N Jain, LJ Croner, JN Allan, T Siddiqi, A Tedeschi… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We …